A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Study Details
Study Description
Brief Summary
The main aim of this study is to evaluate the rates of adverse events of special interest (AESIs) (thrombotic events, acute kidney injury [AKI], and hemolytic events) among participants with CIDP initiating GGL compared with rates among participants with CIDP initiating comparator intravenous immunoglobulin (IVIG) products.
No study medicines will be provided to participants in this study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Ig-naive (New-to-class) Cohort Participants who initiate GGL or one of the comparator IVIG products who have no record of previous use of any Ig product (Ig naive) for at least 6 months before study initiation will be include in this cohort. |
|
| Ig-experienced (New-to-drug) Cohort Participants who initiate either GGL or a comparator IVIG product with no record of previous use of that specific IVIG product but with previous use of any other Ig product (Ig experienced) in all available study data will be included in this cohort. |
Outcome Measures
Primary Outcome Measures
- Number of Participants With Thrombotic Events (TEs) [Throughout observational period, from 01 January 2008 to 31 December 2019 (Up to 12 years)]
Thrombotic events will be reported as adverse events of special interest (AESI) and will include: acute ischemic stroke, acute myocardial infarction (AMI), and acute venous thromboembolism (VTE) events including (deep vein thrombosis (DVT), cerebral venous thrombosis (CVT), pulmonary embolism (PE).
- Number of Participants With Acute kidney injury (AKI) [Throughout observational period, from 01 January 2008 to 31 December 2019 (Up to 12 years)]
AKI will be reported as AESI and will include acute renal failure.
- Number of Participants With Hemolytic Events (HEs) [Throughout observational period, from 01 January 2008 to 31 December 2019 (Up to 12 years)]
HEs will be reported as AESI and will include nonautoimmune hemolytic anemia, acquired hemolytic anemia, ABO incompatibility reaction, or hemolytic transfusion reaction.
Secondary Outcome Measures
- Number of Participants With Anaphylaxis [Throughout observational period, from 01 January 2008 to 31 December 2019 (Up to 12 years)]
Anaphylaxis will be reported as adverse event (AE) and will include anaphylactic reaction or anaphylactic shock.
- Number of Participants With Transfusion-related Acute Lung Injury (TRALI) [Throughout observational period, from 01 January 2008 to 31 December 2019 (Up to 12 years)]
Number of participants with TRALI will be reported.
- Number of Participants With Transfusion-associated Circulatory Overload (TACO) [Throughout observational period, from 01 January 2008 to 31 December 2019 (Up to 12 years)]
Number of participants with TACO will be reported.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Have a minimum of 6 months of continuous enrollment in the study database with medical and pharmacy coverage before the index date. Gaps in continuous enrollment less than or equal to (<=) 31 days are permitted.
-
Fulfill the Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) diagnosis algorithm on or before the index date using all available baseline data for each participant.
-
Additionally, to be eligible for the Ig-naive (new-to-class) cohort, participants will be required to meet the following inclusion criterion:
-
Be free of any previous recorded use of any Ig product at any point before IVIG initiation.
-
To be eligible for the Ig-experienced (new-to-drug) cohort, participants will be required to meet the following inclusion criterion:
-
Have any previous recorded use of an Ig product at any point before the index date.
Exclusion Criteria:
-
Having claims for greater than or equal to (>=) 2 different IVIG products on the index date.
-
Recorded diagnosis of any of the following conditions where Ig products are used for treatment on or before the index date
-
Primary immunodeficiency disease (PID).
-
Evidence of secondary immunodeficiency (SID), including hematological malignancy (e.g., diagnosis of multiple myeloma or chronic lymphocytic leukemia) or treatment with rituximab.
-
Idiopathic thrombocytopenic purpura (ITP).
-
Dermatomyositis or polymyositis.
-
Systemic sclerosis/scleroderma.
-
Myasthenia gravis.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | RTI Health Solutions | Durham | North Carolina | United States | 12194 |
Sponsors and Collaborators
- Takeda
- Baxalta Innovations GmbH, now part of Shire
- RTI Health Solutions
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- TAK-771-4002
- EUPAS46101